Avidity Biosciences, Inc. Common Stock

RNA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
RNA Income Statement
RNA Balance Sheet
RNA Cash Flow
Congress Trading

Recent trades of RNA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
RNA Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
RNA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
RNA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RNA's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Oct. 01, 2024
  • Patent Title: Anti-transferrin receptor antibody-pmo conjugates for inducing dmd exon 44 skipping Aug. 27, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Aug. 27, 2024
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 20, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jul. 30, 2024
  • Patent Title: Una amidites and uses thereof Jun. 11, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jun. 04, 2024
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Feb. 27, 2024
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 16, 2024
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Dec. 05, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Aug. 01, 2023
  • Patent Title: Compositions and methods of treating muscle dystrophy Jul. 25, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 21, 2023
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 14, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 14, 2023
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 17, 2023
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 17, 2023
  • Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 13, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Nov. 15, 2022
  • Patent Title: Compositions and methods of treating muscle dystrophy Sep. 20, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 02, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jun. 21, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Apr. 26, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 22, 2022
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 15, 2022
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Nov. 23, 2021
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 07, 2021
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Jun. 08, 2021
  • Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping May. 04, 2021
  • Patent Title: Anti-transferrin receptor antibodies and uses thereof Feb. 09, 2021
  • Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 05, 2021
  • Patent Title: Egfr nucleic acids and uses thereof Dec. 29, 2020
  • Patent Title: Kras nucleic acids and uses thereof Dec. 08, 2020
  • Patent Title: Beta-catenin nucleic acids and uses thereof Nov. 24, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Oct. 13, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 29, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 04, 2020
  • Patent Title: Nucleic acid-polypeptide compositions and uses thereof Nov. 26, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of RNA in WallStreetBets Daily Discussion

RNA News

Recent insights relating to RNA

CNBC Recommendations

Recent picks made for RNA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RNA

RNA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view RNA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top